Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first ...

Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025 July 27, 2025, 10:31 pm EDT Share Resize ...

Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025 Provided by PR Newswire Jul 27, 2025, 7:31:00 PM ...

Details of the Poster Presentation: ATG-022 (Claudin 18.2 antibody-drug conjugate) Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction ...

Posters will be grouped together by college, and each poster will be assigned a unique location number. The poster presentation schedule will be available on the Symposium website no later than Friday ...

We offer flexible funding options (grants) for undergraduates and faculty to form partnerships for projects in all majors, fields of study and professional practice; host engaging events for students, ...

There is an increasing nationwide demand for certification credentials in the environmental arena. Besides natural resource management, ecological expertise is needed on a host of other current ...

Details of the Poster Presentation: ATG-022 (Claudin 18.2 antibody-drug conjugate) Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction ...

Abstract Number: 2907 Presentation Number: 2113P Date: October 19, 2025 About ATG-022 ATG-022 is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a member of the Claudin family of cell ...